Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Winblad, Roy Jones, Y. Wirth, A. Stöffler, H. Möbius (2007)
Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical TrialsDementia and Geriatric Cognitive Disorders, 24
J. Olazarán, Rubén Muñiz, B. Reisberg, J. Peña-Casanova, T. Ser, Alfonso Cruz-Jentoft, P. Serrano, E. Navarro, M. Rocha, A. Frank, M. Galiano, Y. Fernández-Bullido, J. Serra, M. González-Salvador, C. Sevilla (2004)
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer diseaseNeurology, 63
R. Mohs, R. Doody, J. Morris, J. Ieni, S. Rogers, C. Perdomo, R. Pratt (2001)
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patientsNeurology, 57
L. Clare, R. Woods, E. Moniz-Cook, M. Orrell, A. Spector (2001)
Cognitive rehabilitation interventions targeting memory functioning in early-stage Alzheimer's disease and vascular dementia
P. Tariot, M. Farlow, G. Grossberg (2004)
Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donezepilJAMA, 291
O. Hanon, F. Forette (2004)
Prevention of dementia: lessons from SYST-EUR and PROGRESSJournal of the Neurological Sciences, 226
B. Winblad, K. Engelad, H. Soinen (2001)
A 1-year randomized placebo-controlled study of donezepil in patients with mild moderate Alzheimer’s diseaseNeurology, 57
B. Winblad, L. Kilander, S. Eriksson, L. Minthon, Stellan Båtsman, A.-L. Wetterholm, C. Jansson-Blixt, A. Haglund (2006)
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled studyThe Lancet, 367
H. Brodaty, A. Green, A. Koschera (2003)
Meta‐Analysis of Psychosocial Interventions for Caregivers of People with DementiaJournal of the American Geriatrics Society, 51
J. Rotrou (2008)
Gérontologie préventive
S. Adam, Martial Linden, A. Juillerat, E. Salmon (2000)
The cognitive management of daily life activities in patients with mild to moderate Alzheimer's disease in a day care centre: A case reportNeuropsychological Rehabilitation, 10
R. Howard, E. Juszczak, C. Ballard, P. Bentham, Richard Brown, R. Bullock, A. Burns, C. Holmes, R. Jacoby, T. Johnson, M. Knapp, J. Lindesay, J. O'Brien, G. Wilcock, C. Katona, Roy Jones, Julia DeCesare, M. Rodger (2007)
Donepezil for the treatment of agitation in Alzheimer's disease.The New England journal of medicine, 357 14
A. Vink, Manon Bruinsma, R. Scholten (2003)
Music therapy for people with dementia.The Cochrane database of systematic reviews, 3
D. Wilkinson, A. Passmore, R. Bullock, SW Hopker, R. Smith, Fcv Potocnik, CM Maud, I. Engelbrecht, C. Hock, JR Ieni, RS Bahra (2002)
A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASEInternational Journal of Clinical Practice, 56
D. Geldmacher, G. Provenzano, T. McRae, V. Mastey, J. Ieni (2003)
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's DiseaseJournal of the American Geriatrics Society, 51
R. Bullock, J. Touchon, H. Bergman, G. Gambina, Yunsheng He, G. Rapatz, J. Nagel, R. Lane (2005)
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year periodCurrent Medical Research and Opinion, 21
S. Auriacombe, J. Pere (2003)
No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment *Current Medical Research and Opinion, 19
Paola Gasio, K. Kräuchi, C. Cajochen, E. Someren, Isabelle Amrhein, M. Pache, E. Savaskan, A. Wirz-Justice (2003)
Dawn–dusk simulation light therapy of disturbed circadian rest–activity cycles in demented elderlyExperimental Gerontology, 38
T. Rousseau (1998)
Thérapie cognitivocomportementale des troubles de la communication dans la démence de type alzheimerRev Fr Psychiatrie Psychol Med, 20
D. Cooke, L. McNally, K. Mulligan, M. Harrison, S. Newman (2001)
Psychosocial interventions for caregivers of people with dementia: a systematic review.Aging & mental health, 5 2
S. Gildman, M. Koller, R. Back (2003)
Clinical effects of Aβ immunization (AN1792) in patients with Alzheimer’s disease in an interrupted trialNeurology, 61
S. Gauthier (2005)
Realizing early treatment benefits in dementiaEuropean Journal of Neurology, 12
J. Orgogozo, S. Gilman, J. Dartigues, Bernard Laurent, M. Puel, L. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B. Michel, M. Boada, A. Frank, C. Hock (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunizationNeurology, 61
M. Brotons, S. Koger (2000)
The impact of music therapy on language functioning in dementia.Journal of music therapy, 37 3
D.G. Wilkinson, A.P. Passmore, R. Bullock (2002)
Étude multinationale, randomisée, de 12 semaines, comparant le donepezil et la rivastigmine chez de patients atteints de la maladie d’Alzheimer d’intensité légère à modéréeInt J Clin Pract, 56
S. Gauthier (2005)
Alzheimer's disease: the benefits of early treatmentEuropean Journal of Neurology, 12
Clive Holmes, David Wilkinson, C. Dean, S. Vethanayagam, S. Olivieri, A.N.D. Langley, N. Pandita-Gunawardena, F. Hogg, C. Clare, J. Damms (2004)
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer diseaseNeurology, 63
B. Winblad, K. Engedal, H. Soininen, F. Verhey, G. Waldemar, A. Wimo, A.-L. Wetterholm, R. Zhang, A. Haglund, P. Subbiah (2001)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology, 57
B. Winblad (2006)
Donepezil for severe Alzheimer's disease – Author's replyThe Lancet, 368
C. Ritchie, D. Ames, T. Clayton, R. Lai (2004)
Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 12 4
Francesca Holt, Theodore Birks, L. Thorgrimsen, A. Spector, Anne Wiles, M. Orrell (2003)
Aroma therapy for dementia.The Cochrane database of systematic reviews, 3
B. Woods, L. Thorgrimsen, A. Spector, L. Royan, M. Orrell (2006)
Improved quality of life and cognitive stimulation therapy in dementiaAging & Mental Health, 10
P. Tariot, M. Farlow, G. Grossberg, S. Graham, S. McDonald, I. Gergel (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.JAMA, 291 3
S. Ancoli-Israel, Jennifer Martin, D. Kripke, M. Marler, M. Klauber (2002)
Effect of Light Treatment on Sleep and Circadian Rhythms in Demented Nursing Home PatientsJournal of the American Geriatrics Society, 50
C. Courtney, D. Farrell, R. Gray, R. Hills, Lloyd Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw, P. Bentham (2004)
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trialThe Lancet, 363
L. Clare, R. Woods, ED Cook, M. Orrell, A. Spector (2003)
Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia.The Cochrane database of systematic reviews, 4
Face à l’augmentation dramatique du nombre de patients touchés par la maladie d’Alzheimer, de nombreuses voies de recherche, médicamenteuses ou non, se sont développées au cours des 20 dernières années. Certaines ont abouti à la commercialisation de traitements médicamenteux symptomatiques comme les anticholinestérasiques ou la mémantine. Leur intérêt, leurs limites comme leurs modalités de prescription doivent être bien connus des praticiens, qu’ils en soient les initiateurs ou non. Les thérapies d’avenir explorent des voies curatives intervenant directement sur les lésions cérébrales et des pistes préventives afin d’éviter l’apparition de la maladie chez les sujets à risque. Parallèlement et de façon complémentaire aux traitements médicamenteux, différentes modalités d’interventions non pharmacologiques, individuelles ou collectives, ont émergé. Deux grandes orientations d’intervention sont bien définies à partir de cadrages théoriques différents, de type « rééducation » et « stimulation ». Plus récemment, se sont développées des modalités de prise en charge de type « activité physique ». L’apport de ces prises en charge fait également l’objet d’évaluations rigoureuses.
PSN – Springer Journals
Published: May 26, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.